AsedaSciences and GenEvolutioN Announce Sales & Marketing Agreement to Integrate Genotoxicity Screen into 3RnD Platform
AsedaSciences announced a sales and marketing agreement with GenEvolutioN to integrate their genotoxicity screen into the 3RnD digital platform for chemical toxicity risk prediction178.
This partnership supports the global shift from animal testing to New Approach Methods (NAMs) by centralizing validated assays in a unified ecosystem1.
The announcement appears alongside similar recent deals by AsedaSciences, such as with Xenometrix for Ames test and Clyde Biosciences for cardiotoxicity screening24.
Sources:
1. https://sars.einnews.com/pr_news/886769228/asedasciences-and-genevolution-announce-sales-marketing-agreement-to-integrate-genotoxicity-screen-into-3rnd-platform
2. https://www.einpresswire.com/article/886774883/asedasciences-and-xenometrix-announce-strategic-sales-marketing-agreement-to-integrate-ames-test-into-3rnd-platform?code=4CJrSfjuxglMwzMc
4. https://www.einpresswire.com/article/886781822/asedasciences-and-clyde-biosciences-announce-commercial-agreement-to-integrate-human-relevant-cardiotoxicity-screening